NeuroVive completes closure of Lyon subsidiary
Lund, Sweden, October 25, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that it has completed the closure of its dormant subsidiary in Lyon, France.
The closure of the subsidiary NeuroVive France SARL is a natural consequence of the company’s previously communicated decision that it will not pursue development of CicloMulsion®.
Accordingly, all agreements related to the research partnership with Hospices Civils de Lyon (HCL) and Professor Michel Ovize, including the OPeRa (Organ Protection & Replacement) have been terminated.
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, drug development and production expertise, as well as commercial partners.
NeuroVive has a project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to neurological and metabolic diseases.
NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).
For investor relations and media questions, please contact:
Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or firstname.lastname@example.org
Charles Athle Nelson, NeuroVive US representative, Tel +1 212 961 6277 or email@example.com
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on Oct 25, 2016.